Bioorthogonal, two-component delivery systems based on antibody and drug-loaded nanocarriers for enhanced internalization of nanotherapeutics

Biomaterials

Volumn 35, Issue 7, 2014, Pages 2346-2354

  Hapuarachchige, Sudath ^a   Zhu, Wenlian ^a   Kato, Yoshinori ^a,b   Artemov, Dmitri ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Bioorthogonal click chemistry; Drug delivery; Nanocarriers; Targeted therapy

Indexed keywords

CELL MEMBRANES; CHEMOTHERAPY; CONTROLLED DRUG DELIVERY; CROSSLINKING; CYTOLOGY; CYTOTOXICITY; DISEASES; DRUG DELIVERY; MONOCLONAL ANTIBODIES;

BREAST CANCER CELLS; CELLULAR INTERNALIZATION; CLICK CHEMISTRY; HUMANIZED MONOCLONAL ANTIBODY; NANO-CARRIERS; SPECIFIC RECOGNITION; TARGETED DELIVERY SYSTEMS; TARGETED THERAPY;

TARGETED DRUG DELIVERY;

ALBUMIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; NANOCARRIER; PACLITAXEL; TRASTUZUMAB;

ARTICLE; BINDING AFFINITY; BREAST CANCER; CANCER CELL; CELL VIABILITY; CLICK CHEMISTRY; COMPLEX FORMATION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG POTENTIATION; FLUORESCENCE IMAGING; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

BIOORTHOGONAL CLICK CHEMISTRY; DRUG DELIVERY; HER2(+) BREAST CANCER; NANOCARRIERS; TARGETED THERAPY;

ANTIBODIES; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CLICK CHEMISTRY; DRUG DELIVERY SYSTEMS; HUMANS; MICROSCOPY, CONFOCAL; NANOTECHNOLOGY; PACLITAXEL; RECEPTOR, ERBB-2; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 84891372429     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.11.075     Document Type: Article

References (42)

1. Gelperina S., Kisich K., Iseman M.D., Heifets L. The potential advantages of nanoparticle drug delivery systems in chemotherapy of tuberculosis. Am J Respir Crit Care Med 2005, 172:1487-1490.
2. Kuykendall D.W., Zimmerman S.C. Nanoparticles - a very versatile nanocapsule. Nat Nanotechnol 2007, 2:201-202.
3. Sanhai W.R., Sakamoto J.H., Canady R., Ferrari M. Seven challenges for nanomedicine. Nat Nanotechnol 2008, 3:242-244.
4. Singh S., Sharma A., Robertson G.P. Realizing the clinical potential of cancer nanotechnology by minimizing toxicologic and targeted delivery concerns. Cancer Res 2012, 72:5663-5668.
5. Yokoyama M. Drug targeting with nano-sized carrier systems. JArtif Organs 2005, 8:77-84.
6. De Jong W.H., Borm P.J.A. Drug delivery and nanoparticles: applications and hazards. Int J Nanomed 2008, 3:133-149.
7. Peer D., Karp J.M., Hong S., FaroKHzad O.C., Margalit R., Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2007, 2:751-760.
8. Sievers E.L., Senter P.D. Antibody-drug conjugates in cancer therapy. Annu Rev Med 2013, 64:15-29.
9. Cho H.S., Mason K., Ramyar K.X., Stanley A.M., Gabelli S.B., Denney D.W., et al. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 2003, 421:756-760.
10. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., Mcguire W.L. Human-breast cancer - correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235:177-182.
11. Lee-Hoeflich S.T., Crocker L., Yao E., Pham T., Munroe X., Hoeflich K.P., et al. Acentral role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res 2008, 68:5878-5887.
12. Zaczek A., Brandt B., Bielawski K.P. The diverse signaling network of EGFR, HER2, HER3 and HER4 tyrosine kinase receptors and the consequences for therapeutic approaches. Histol Histopathol 2005, 20:1005-1015.
13. Buschenfelde C.M., Hermann C., Schmidt B., Peschel C., Bernhard H. Antihuman epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab enhances cytolytic activity of class I-restricted HER2-specific T lymphocytes against HER2-overexpressing tumor cells. Cancer Res 2002, 62:2244-2247.
14. Zhang S.Y., Huang W.C., Li P., Guo H., Poh S.B., Brady S.W., et al. Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways. Nat Med 2011, 17:461-470.
15. Pohlmann P.R., Mayer I.A., Mernaugh R. Resistance to trastuzumab in breast cancer. Clin Cancer Res 2009, 15:7479-7491.
16. Hommelgaard A.M., Lerdrup M., van Deurs B. Association with membrane protrusions makes ErbB2 an internalization-resistant receptor. Mol Biol Cell 2004, 15:1557-1567.
17. Girish S., Gupta M., Wang B., Lu D., Krop I.E., Vogel C.L., et al. Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer. Cancer Chemother Pharmacol 2012, 69:1229-1240.
18. Burris H.A., Rugo H.S., Vukelja S.J., Vogel C.L., Borson R.A., Limentani S., et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. JClin Oncol 2011, 29:398-405.
19. Muller V., Witzel I., Stickeler E. Immunological approaches in the treatment of metastasized breast cancer. Breast Care 2009, 4:358-366.
20. Hamblett K.J., Senter P.D., Chace D.F., Sun M.M.C., Lenox J., Cerveny C.G., et al. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin Cancer Res 2004, 10:7063-7070.
21. Junutula J.R., Raab H., Clark S., Bhakta S., Leipold D.D., Weir S., et al. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat Biotechnol 2008, 26:925-932.
22. Janthur W.D., Cantoni N., Mamot C. Drug conjugates such as antibody drug conjugates (ADCs), immunotoxins and immunoliposomes challenge daily clinical practice. Int J Mol Sci 2012, 13:16020-16045.
23. Krop I.E., Beeram M., Modi S., Jones S.F., Holden S.N., Yu W., et al. Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. JClin Oncol 2010, 28:2698-2704.
24. Lyass O., Uziely B., Ben-Yosef R., Tzemach D., Heshing N.I., Lotem M., et al. Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma. Cancer 2000, 89:1037-1047.
25. Chan D.P.Y., Deleavey G.F., Owen S.C., Damha M.J., Shoichet M.S. Click conjugated polymeric immuno-nanoparticles for targeted siRNA and antisense oligonucleotide delivery. Biomaterials 2013, 34:8408-8415.
26. Wiseman L.R., Spencer C.M. Paclitaxel - an update of its use in the treatment of metastatic breast cancer and ovarian and other gynaecological cancers. Drugs Aging 1998, 12:305-334.
27. Boddy A.V., Plummer E.R., Todd R., Sludden J., Griffin M., Robson L., et al. Aphase I and pharmacokinetic study of paclitaxel poliglumex (XYOTAX), investigating both 3-weekly and 2-weekly schedules. Clin Cancer Res 2005, 11:7834-7840.
28. Gelderblom H., Verweij J., Nooter K., Sparreboom A., Cremophor E.L. The drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 2001, 37:1590-1598.
29. Fu Q., Sun J., Zhang W.P., Sui X.F., Yan Z.T., He Z.G. Nanoparticle albumin-bound (NAB) technology is a promising method for anti-cancer drug delivery. Recent Pat Anti-Canc 2009, 4:262-272.
30. Stinchcombe T.E. Nanoparticle albumin-bound paclitaxel: a novel Cremphor-EL-free formulation of paclitaxel. Nanomedicine-UK 2007, 2:415-423.
31. Yamada K. Clinical development of abraxane, albumin-bound paclitaxel. Drug Deliv Syst 2009, 24:38-44.
32. Gradishar W.J. Albumin-bound paclitaxel: a next-generation taxane. Expert Opin Pharmacother 2006, 7:1041-1053.
33. Kratz F. Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. JControl Release 2008, 132:171-183.
34. Baskin J.M., Prescher J.A., Laughlin S.T., Agard N.J., Chang P.V., Miller I.A., et al. Copper-free click chemistry for dynamic invivo imaging. Proc Natl Acad Sci U S A 2007, 104:16793-16797.
35. Chang P.V., Prescher J.A., Sletten E.M., Baskin J.M., Miller I.A., Agard N.J., et al. Copper-free click chemistry in living animals. Proc Natl Acad Sci U S A 2010, 107:1821-1826.
36. Koo H., Lee S., Na J.H., Kim S.H., Hahn S.K., Choi K., et al. Bioorthogonal copper-free click chemistry invivo for tumor-targeted delivery of nanoparticles. Angew Chem Int Ed Engl 2012, 51:11836-11840.
37. Haun J.B., Devaraj N.K., Hilderbrand S.A., Lee H., Weissleder R. Bioorthogonal chemistry amplifies nanoparticle binding and enhances the sensitivity of cell detection. Nat Nanotechnol 2010, 5:660-665.
38. Peterson V.M., Castro C.M., Lee H., Weissleder R. Orthogonal amplification of nanoparticles for improved diagnostic sensing. ACS Nano 2012, 6:3506-3513.
39. Dosio F., Brusa P., Crosasso P., Arpicco S., Cattel L. Preparation, characterization and properties invitro and invivo of a paclitaxel-albumin conjugate. JControl Release 1997, 47:293-304.
40. Hong G.S., Wu J.Z., Robinson J.T., Wang H.L., Zhang B., Dai H.J. Three-dimensional imaging of single nanotube molecule endocytosis on plasmonic substrates. Nat Commun 2012, 3.
41. Zhang S.L., Li J., Lykotrafitis G., Bao G., Suresh S. Size-dependent endocytosis of nanoparticles. Adv Mater 2009, 21:419-424.
42. Hillaireau H., Couvreur P. Nanocarriers' entry into the cell: relevance to drug delivery. Cell Mol Life Sci 2009, 66:2873-2896.